Sellas Life Sciences Group (SLS)
NASDAQ:SLS
Total Valuation
SELLAS Life Sciences Group has a market cap or net worth of $741.68M. The enterprise value is $517.39M.
Market Cap$741.68M
Enterprise Value$517.39M
Share Statistics
SELLAS Life Sciences Group has 179,582,580 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding179,582,580
Owned by Insiders1.60%
Owned by Institutions3.01%
Financial Efficiency
SELLAS Life Sciences Group’s return on equity (ROE) is -0.38 and return on invested capital (ROIC) is -39.34%.
Return on Equity (ROE)-0.38
Return on Assets (ROA)-0.34
Return on Invested Capital (ROIC)-39.34%
Return on Capital Employed (ROCE)-0.40
Revenue Per Employee0.00
Profits Per Employee-1.79M
Employee Count15
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of SELLAS Life Sciences Group is ―. SELLAS Life Sciences Group’s PEG ratio is 0.31.
PE Ratio―
PS Ratio0.00
PB Ratio5.80
Price to Fair Value5.80
Price to FCF-14.48
Price to Operating Cash Flow-22.27
PEG Ratio0.31
Income Statement
In the last 12 months, SELLAS Life Sciences Group had revenue of 0.00 and earned -26.86M in profits. Earnings per share was -0.25.
Revenue0.00
Gross Profit0.00
Operating Income-28.27M
Pretax Income-26.86M
Net Income-26.86M
EBITDA-28.27M
Earnings Per Share (EPS)-0.25
Cash Flow
In the last 12 months, operating cash flow was -28.39M and capital expenditures 0.00, giving a free cash flow of -28.39M billion.
Operating Cash Flow-28.39M
Free Cash Flow-28.39M
Free Cash Flow per Share-0.16
Dividends & Yields
SELLAS Life Sciences Group pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.48
52-Week Price Change297.12%
50-Day Moving Average4.55
200-Day Moving Average2.68
Relative Strength Index (RSI)41.90
Average Volume (3m)8.04M
Important Dates
SELLAS Life Sciences Group upcoming earnings date is May 19, 2026, TBA (Confirmed).
Last Earnings DateMar 19, 2026
Next Earnings DateMay 19, 2026
Ex-Dividend Date―
Financial Position
SELLAS Life Sciences Group as a current ratio of 10.72, with Debt / Equity ratio of 1.41%
Current Ratio10.72
Quick Ratio10.72
Debt to Market Cap<0.01
Net Debt to EBITDA2.51
Interest Coverage Ratio0.00
Taxes
In the past 12 months, SELLAS Life Sciences Group has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
SELLAS Life Sciences Group EV to EBITDA ratio is -12.03, with an EV/FCF ratio of -11.98.
EV to Sales0.00
EV to EBITDA-12.03
EV to Free Cash Flow-11.98
EV to Operating Cash Flow-11.98
Balance Sheet
SELLAS Life Sciences Group has $71.89M in cash and marketable securities with $1.00M in debt, giving a net cash position of $70.89M billion.
Cash & Marketable Securities$71.89M
Total Debt$1.00M
Net Cash$70.89M
Net Cash Per Share$0.39
Tangible Book Value Per Share$0.63
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for SELLAS Life Sciences Group is $10.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$10.00
Price Target Upside143.31% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast59.04%